NASDAQ:ICVX Icosavax (ICVX) Stock Forecast, Price & News $7.75 -0.05 (-0.64%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$7.53▼$8.1450-Day Range$7.22▼$9.1752-Week Range$2.28▼$16.45Volume326,103 shsAverage Volume307,286 shsMarket Capitalization$387.86 millionP/E RatioN/ADividend YieldN/APrice Target$27.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Icosavax MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside248.4% Upside$27.00 Price TargetShort InterestBearish3.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 2 Articles This WeekInsider TradingSelling Shares$305,799 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.31) to ($2.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.32 out of 5 starsMedical Sector323rd out of 972 stocksBiological Products, Except Diagnostic Industry43rd out of 153 stocks 3.5 Analyst's Opinion Consensus RatingIcosavax has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.00, Icosavax has a forecasted upside of 248.4% from its current price of $7.75.Amount of Analyst CoverageIcosavax has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.67% of the float of Icosavax has been sold short.Short Interest Ratio / Days to CoverIcosavax has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Icosavax has recently increased by 10.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIcosavax does not currently pay a dividend.Dividend GrowthIcosavax does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ICVX. Previous Next 2.9 News and Social Media Coverage News SentimentIcosavax has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Icosavax this week, compared to 1 article on an average week.Search Interest3 people have searched for ICVX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added Icosavax to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Icosavax insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $305,799.00 in company stock.Percentage Held by Insiders30.59% of the stock of Icosavax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.59% of the stock of Icosavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Icosavax are expected to grow in the coming year, from ($2.31) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Icosavax is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Icosavax is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIcosavax has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Icosavax (NASDAQ:ICVX) StockIcosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.Read More ICVX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ICVX Stock News HeadlinesSeptember 19, 2023 | finance.yahoo.comIcosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023August 15, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Icosavax (ICVX)October 1, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 14, 2023 | finance.yahoo.comIcosavax Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 8, 2023 | finance.yahoo.comIcosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination PotentialJuly 2, 2023 | finance.yahoo.comIcosavax, Inc. (NASDAQ:ICVX) is largely controlled by institutional shareholders who own 53% of the companyJune 20, 2023 | finance.yahoo.comIcosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older AdultsJune 15, 2023 | benzinga.comIcosavax EVP Awarded $1.79M Worth of Stock OptionsOctober 1, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.May 24, 2023 | finance.yahoo.comIcosavax (ICVX) Up on Positive VLP Vaccine Candidate DataMay 23, 2023 | finance.yahoo.comWhy Shares of Icosavax Jumped on TuesdayMay 23, 2023 | msn.comCohBar, Ocean Biomedical top healthcare gainers; NantHealth, Microbot among losersMay 23, 2023 | markets.businessinsider.comIcosavax Touts Encouraging Early-Cut Data From Phase 1 Trial Of RSV VaccineMay 22, 2023 | benzinga.comIcosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older AdultsMay 22, 2023 | finance.yahoo.comIcosavax Announces $67.8 Million Registered Direct Offering of Common StockMay 11, 2023 | finance.yahoo.comShould You Buy Icosavax (ICVX) Ahead of Earnings?May 10, 2023 | finance.yahoo.comIcosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue EstimatesMay 10, 2023 | finance.yahoo.comIcosavax Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 8, 2023 | finance.yahoo.comIcosavax, Inc. (ICVX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?April 25, 2023 | msn.comOppenheimer Reiterates Icosavax (ICVX) Outperform RecommendationMarch 30, 2023 | finance.yahoo.comIcosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateFebruary 28, 2023 | finance.yahoo.comIcosavax to Participate in the Upcoming Healthcare ConferencesFebruary 24, 2023 | finance.yahoo.comIcosavax, Inc. (NASDAQ:ICVX) insider upped their holding by 527% earlier this yearFebruary 21, 2023 | finance.yahoo.comIcosavax Granted FDA Fast Track Designation for IVX-A12January 12, 2023 | finance.yahoo.comIcosavax (NASDAQ:ICVX) adds US$100m to market cap in the past 7 days, though investors from a year ago are still down 38%January 6, 2023 | finance.yahoo.comIcosavax Provides Corporate Update and Anticipated Milestones for 2023December 17, 2022 | reuters.comICVX.O - Icosavax Inc | Stock Price & Latest News | ReutersSee More Headlines Receive ICVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter. Email Address ICVX Company Calendar Last Earnings8/14/2023Today10/01/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ICVX CUSIPN/A CIK1786255 Webicosavax.com Phone206-737-0085FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.00 High Stock Price Forecast$27.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+248.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-91,760,000.00 Net MarginsN/A Pretax Margin-15,765.98% Return on Equity-43.36% Return on Assets-39.80% Debt Debt-to-Equity RatioN/A Current Ratio16.76 Quick Ratio16.76 Sales & Book Value Annual Sales$580,000.00 Price / Sales668.73 Cash FlowN/A Price / Cash FlowN/A Book Value$5.47 per share Price / Book1.42Miscellaneous Outstanding Shares50,047,000Free Float34,738,000Market Cap$387.86 million OptionableNot Optionable Beta0.39 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Adam K. Simpson (Age 47)Pres, CEO, Co-Founder & Director Comp: $855.95kMr. Niranjan Kanesa-thasan M.D. (Age 62)Chief Medical Officer Comp: $641.55kDr. Cassia Cearley Ph.D. (Age 40)Treasurer & Chief Bus. Officer Comp: $632.15kMr. Neil King Ph.D.Chair of Scientific Advisory Board & Co-FounderDr. David Baker M.D.Ph.D., Co-founder & Member of Scientific Advisory BoardMr. Thomas Joseph Russo C.F.A. (Age 51)Chief Financial Officer Ms. Jennifer RaymondSr. VP of Technical OperationsMr. Douglas A. Holtzman M.P.H. (Age 58)Ph.D., Chief Scientific Officer Ms. Elizabeth Bekiroglu (Age 53)Gen. Counsel & Corp. Sec. Ms. Lori StewartSr. VP of People & CultureMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSAutolus TherapeuticsNASDAQ:AUTLCullinan OncologyNASDAQ:CGEMCaribou BiosciencesNASDAQ:CRBUAgenusNASDAQ:AGENView All CompetitorsInsiders & InstitutionsBarclays PLCSold 7,611 shares on 9/21/2023Ownership: 0.011%Nuveen Asset Management LLCBought 48,747 shares on 8/16/2023Ownership: 0.215%Alliancebernstein L.P.Bought 11,350 shares on 8/15/2023Ownership: 0.053%Wells Fargo & Company MNBought 6,507 shares on 8/15/2023Ownership: 0.025%Citadel Advisors LLCSold 2,800 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ICVX Stock - Frequently Asked Questions Should I buy or sell Icosavax stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICVX shares. View ICVX analyst ratings or view top-rated stocks. What is Icosavax's stock price forecast for 2023? 1 equities research analysts have issued 12-month price targets for Icosavax's shares. Their ICVX share price forecasts range from $27.00 to $27.00. On average, they anticipate the company's share price to reach $27.00 in the next year. This suggests a possible upside of 248.4% from the stock's current price. View analysts price targets for ICVX or view top-rated stocks among Wall Street analysts. How have ICVX shares performed in 2023? Icosavax's stock was trading at $7.94 at the beginning of the year. Since then, ICVX stock has decreased by 2.4% and is now trading at $7.75. View the best growth stocks for 2023 here. Are investors shorting Icosavax? Icosavax saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,190,000 shares, an increase of 10.2% from the August 31st total of 1,080,000 shares. Based on an average daily volume of 231,600 shares, the days-to-cover ratio is currently 5.1 days. Currently, 3.7% of the company's shares are short sold. View Icosavax's Short Interest. When is Icosavax's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ICVX earnings forecast. How were Icosavax's earnings last quarter? Icosavax, Inc. (NASDAQ:ICVX) released its earnings results on Monday, August, 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.01. What ETF holds Icosavax's stock ? ETFMG Treatments Testing and Advancements ETF holds 14,037 shares of ICVX stock, representing 0.78% of its portfolio. When did Icosavax IPO? (ICVX) raised $150 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. What is Icosavax's stock symbol? Icosavax trades on the NASDAQ under the ticker symbol "ICVX." How do I buy shares of Icosavax? Shares of ICVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Icosavax's stock price today? One share of ICVX stock can currently be purchased for approximately $7.75. How much money does Icosavax make? Icosavax (NASDAQ:ICVX) has a market capitalization of $387.86 million and generates $580,000.00 in revenue each year. The company earns $-91,760,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. How can I contact Icosavax? The official website for the company is icosavax.com. The company can be reached via phone at 206-737-0085 or via email at ir@icosavax.com. This page (NASDAQ:ICVX) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Icosavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.